Logo
x

Search

Subscribe Now

Ipsen

Ipsen Collaborates with Day One Biopharmaceuticals for the commercialization of Tovorafenib to Treat Pediatric Low-Grade Glioma

Ipsen Collaborates with Day One Biopharmaceuticals for the commercialization of Tovorafenib to Treat Pediatric Low-Grade Glioma

  • July 25, 2024
Ipsen Teams Up with Foreseen Biotechnology to Develop FS001 for Solid Tumors

Ipsen Teams Up with Foreseen Biotechnology to Develop FS001 for Solid Tumors

  • July 11, 2024
Ipsen Reports Collaboration Expansion with Exelixis to Develop Cabometyx for Treating Neuroendocrine Tumors

Ipsen Reports Collaboration Expansion with Exelixis to Develop Cabometyx for Treating Neuroendocrine Tumors

  • July 2, 2024
Ipsen’s Iqirvo (Elafibranor) Gains the US FDA’s Accelerated Approval for Treating Primary Biliary Cholangitis

Ipsen’s Iqirvo (Elafibranor) Gains the US FDA’s Accelerated Approval for Treating Primary Biliary Cholangitis

  • June 11, 2024
Ipsen Enters into an Option Agreement with Skyhawk Therapeutics for Two RNA Targeting Small Molecules in Rare Neurological Diseases

Ipsen Enters into an Option Agreement with Skyhawk Therapeutics for Two RNA Targeting Small Molecules in Rare Neurological Disease...

  • April 22, 2024
Ipsen and Sutro Biopharma Collaborate to Develop and Commercialize STRO-003 for Treating Solid Tumors

Ipsen and Sutro Biopharma Collaborate to Develop and Commercialize STRO-003 for Treating Solid Tumors

  • April 2, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.